

Myval, Pulmonary and Cardiac Rehabilitation, Pulmonary Embolism...

Myval is a balloon-expandable valve used in trans catheter aortic valve implantation (TAVI) with distinguished features. Data comparing Myval with contemporary trans catheter heart valves (THV) is limited. Mansuri et al from India performed a meta-analysis of studies comparing Myval with contemporary THVs (Sapien series and Evolut series). Which one is better?

Şafak et al from Türkiye evaluated the effects of pulmonary rehabilitation on respiratory and echocardiographic parameters in patients with primary lung disease. Look at the improvement in both respiratory and cardiac functions and quality of life.

Luo et al from China discussed that Serum miR-212-3p might serve as a non-invasive biomarker for ACS diagnosis and MACE prediction, and as a supplementary molecular tool in clinical practice.

Patients with rheumatoid arthritis (RA) have an increased risk of developing cardiovascular disease (CVD). However, the mechanisms underlying the comorbidity between RA and CVD remain poorly understood. Bai et al from China tried to identify the shared genes between RA and CVD, and to explore their functional relationships.

Intermediate-high-risk pulmonary embolism is defined by right ventricular dysfunction and elevated cardiac troponin in the absence of hemodynamic instability. While full-dose thrombolysis may improve outcomes, it poses a high bleeding risk. So Kültürsay et al from Türkiye assessed the safety and efficacy of a reduced-dose, slow-infusion thrombolytic regimen. What happened?

Li et al from China investigated the impacts of cardiac rehabilitation exercise plus sacubitril valsartan sodium on cardiac function, lung function as well as quality of life in chronic heart failure patients. The hypothesis was that sacubitril/valsartan's hemodynamic stabilization would enable safer exercise tolerance, while rehabilitation could potentiate its endothelial-protective effects through shear stress-mediated NO release.

And a case report, letters, e-page original.

I hope this new issue of our journal will be interest of our readers.

EDITORIAL

Çetin Erol

Editor-in-Chief, Ankara, Türkiye



Copyright©Author(s) - Available online at anatoljcardiol.com.
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

DOI: 10.14744/AnatolJCardiol.2025.12